The Government Has Green-Lit a Major Change to 340B Payments … With Some Limits

I mentioned yesterday that Merck had dropped its annual drug-price transparency report, warning that Merck’s numbers probably shouldn’t be extrapolated to the broader industry. After all, most companies don’t have

Another late one. Some days, I feel like Inigo Montoya: “There is too much.” Yesterday, Charles River Laboratories, which provides tools and services to help companies do R&D, warned analysts

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv